BioAtla, Inc. (BCAB): Price and Financial Metrics
BCAB Price/Volume Stats
| Current price | $2.35 | 52-week high | $4.07 |
| Prev. close | $2.24 | 52-week low | $1.24 |
| Day low | $2.24 | Volume | 395,700 |
| Day high | $2.38 | Avg. volume | 510,059 |
| 50-day MA | $2.78 | Dividend yield | N/A |
| 200-day MA | $2.31 | Market Cap | 113.03M |
BCAB Stock Price Chart Interactive Chart >
BioAtla, Inc. (BCAB) Company Bio
BioAtla LLC develops conditionally active biologic antibody therapeutics. The firm's technologies include conditionally active biologics, comprehensive integrated antibody optimization, CPE and CPS, gigamab, and versitop. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Latest BCAB News From Around the Web
Below are the latest news stories about BIOATLA INC that investors may wish to consider to help them evaluate BCAB as an investment opportunity.
Co-Founder of BioAtla Jay Short Buys 2.3% More SharesInvestors who take an interest in BioAtla, Inc. ( NASDAQ:BCAB ) should definitely note that the Co-Founder, Jay Short... |
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceSAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the 42nd Annual J.P. Morgan Healthcare Conference, to be held in San Francisco, CA January 8-11, 2024. Format: Fireside chat and scheduled |
After losing 78% in the past year, BioAtla, Inc. (NASDAQ:BCAB) institutional owners must be relieved by the recent gainKey Insights Significantly high institutional ownership implies BioAtla's stock price is sensitive to their trading... |
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor TypesMultiple confirmed responses and durable disease control observed Emerging differentiated safety profile enables further exploration at higher doses Ongoing Phase 2 clinical study of monotherapy and in combination with a PD-1 inhibitor SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today is hosting a v |
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced it will host a virtual R&D Day on Wednesday, December 13, 2023 at 10:00 AM ET. To register, click here. The event will feature Omid Hamid, MD (Cedars Sinai: The Angeles Clinic and Research Institute), who will review Phase 1 dose escalation |
BCAB Price Returns
| 1-mo | -21.93% |
| 3-mo | 14.08% |
| 6-mo | 85.04% |
| 1-year | -30.47% |
| 3-year | -95.66% |
| 5-year | N/A |
| YTD | -4.47% |
| 2023 | -70.18% |
| 2022 | -57.97% |
| 2021 | -42.28% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...